Table 1.
Study characteristics.
| Study Description | Intervention | Persons Analyzed | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Reference/Year/Country/Sponsorship | Blinding/Crossover (Y/N)/Multi-Arm > 2 | Focus on | ROB | The Form of Supplement | Curcumin Dose/(mg/day) | Duration of Administration (days)/Comparator | N Total Randomized/Analyzed | Age Years (Mean ± SD) | Males (n/%) |
| Saraf-Bank/2019/Iran/Academia | SB/N/N | MDA, TCA | 5 | Pills | 500 | 70/placebo | 60/60 | 16.001 ± 1.64 | 0/0 |
| Alizadeh/2017/Iran/Academia | DB/N/N | MDA, TCA | 5 | Nanomicelle | 80 | 70/placebo | 60/56 | 30.27 ± 4.00 | 60/100 |
| Ghazimoradi/2017/Iran/Academia | DB/N/N | PAB | 4 | Pills | 1000 | 42/placebo | 120/109 | 38.05 ± 2.89 | 19/17.43 |
| Nasseri/2017/Iran/Academia | DB/N/N | MDA, TAC, Catalase | 2 | Pills | 1000 | 84/placebo | 68/61 | 26.80 ± 6.64 | 26/42.62 |
DB—double blind; SB—single blind; N—no; Y—yes; NA—not applicable; ROB—risk of bias; SD—standard deviation; MDA—malondialdehyde; TAC—total antioxidant capacity; PAB—pro-oxidant–antioxidant balance.